Last reviewed · How we verify
Bicillin C-R — Competitive Intelligence Brief
marketed
Beta-lactam antibiotic
Cell-wall peptidoglycan biosynthesis
Small molecule
Live · refreshed every 30 min
Target snapshot
Bicillin C-R (Penicillin G Benzathine) — Pfizer. Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bicillin C-R TARGET | Penicillin G Benzathine | Pfizer | marketed | Beta-lactam antibiotic | Cell-wall peptidoglycan biosynthesis | 1952-01-01 |
| Bicillin C-R | Penicillin G Benzathine | Pfizer | marketed | Beta-lactam antibiotic | Cell-wall peptidoglycan biosynthesis | 1952-01-01 |
| Bicillin C-R | Penicillin G Benzathine | Pfizer Inc. | marketed | Beta-lactam antibiotic | Cell-wall peptidoglycan biosynthesis | |
| Amoxil | amoxicillin | Generic (originally Beecham/GSK) | marketed | Aminopenicillin (Beta-lactam antibiotic) | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C | 1972-01-01 |
| Vonoprazan-Amoxicillin with Berberine | Vonoprazan-Amoxicillin with Berberine | Nanjing First Hospital, Nanjing Medical University | marketed | H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial) | H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); multiple H. pylori targets (berberine) | |
| cefoperazone sodium and sulbactam sodium | cefoperazone sodium and sulbactam sodium | Yung Shin Pharm. Ind. Co., Ltd. | marketed | Beta-lactam antibiotic with beta-lactamase inhibitor | Bacterial penicillin-binding proteins; beta-lactamases | |
| Vonoprazan+amoxicillin 14 days | Vonoprazan+amoxicillin 14 days | Xijing Hospital of Digestive Diseases | marketed | Potassium-competitive acid blocker + beta-lactam antibiotic combination | H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Amoxil · 8778924 · Compound · US
- — Amoxil · 8357394 · Formulation · US
- — Amoxil · 8299052 · Method of Use · US
Sponsor landscape (Beta-lactam antibiotic class)
- Pfizer · 2 drugs in this class
- Bayer · 1 drug in this class
- Belén Retamal-Valdes · 1 drug in this class
- Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
- Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
- Incheon St.Mary's Hospital · 1 drug in this class
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
- KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
- National Taiwan University Hospital · 1 drug in this class
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bicillin C-R CI watch — RSS
- Bicillin C-R CI watch — Atom
- Bicillin C-R CI watch — JSON
- Bicillin C-R alone — RSS
- Whole Beta-lactam antibiotic class — RSS
Cite this brief
Drug Landscape (2026). Bicillin C-R — Competitive Intelligence Brief. https://druglandscape.com/ci/bicillin-l-a. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab